Strides To By 74% Of Bafna Domestic Business For $8 Million
This article was originally published in PharmAsia News
Executive Summary
Strides Arcolab said it plans to spend about $8 million to buy 74% of Bafna Pharmaceutical's domestic business to gain access to its formulations, which Bafna is to continue producing for Strides.